Skip to content
1st Counsel – Lifestyle
Author:
NS Pharma, Inc.
Brogidirsen (NS-089/NCNP-02) 5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2026 World Muscle Society Congress
October 1, 2026
NS Pharma Parent Company, Nippon Shinyaku, Exercises Option Rights for Commercialization of AB2 BIO’s Tadekinig alfa in the U.S.
July 30, 2026
Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
June 26, 2026
NS Pharma Parent Company, Nippon Shinyaku, Announces Sponsored Research Agreement with Boston Children’s Hospital
June 23, 2026